We also demonstrated that recruitment of CXCR2+ myeloid cells to SMAD4-deficient CRCs could promote tumor invasion and metastasis, suggesting blockade of the CXCL1/8–CXCR2 axis could be a novel therapeutic approach in CRC [20]. The gene discussed is CXCR2; the disease is neoplasm.